Valuation: Alpha Cognition Inc.

Market Cap 294M 212M 182M 170M 156M 20.23B 297M 2.01B 782M 10.21B 797M 779M 33.8B P/E 2026 *
-7.42x
P/E 2027 * -15.8x
Enterprise Value 294M 212M 182M 170M 156M 20.23B 297M 2.01B 782M 10.21B 797M 779M 33.8B EV / Sales 2026 *
8.22x
EV / Sales 2027 * 4.29x
Free-Float
94.72%
Yield 2026 *
-
Yield 2027 * -
1 day-1.85%
1 week+11.66%
Current month+15.64%
1 month+11.60%
3 months+62.84%
6 months+51.14%
Current year+47.31%
1 week 8.53
Extreme 8.5301
10.14
1 month 7.54
Extreme 7.539
10.14
Current year 4.5
Extreme 4.5
10.14
1 year 4.5
Extreme 4.5
10.14
3 years 3.75
Extreme 3.75
18.5
5 years 3.5
Extreme 3.5025
43.25
10 years 3.5
Extreme 3.5025
45
Manager TitleAgeSince
Chief Executive Officer 58 2021-04-11
Chief Tech/Sci/R&D Officer - 2021-03-21
Director of Finance/CFO 48 2024-10-20
Director TitleAgeSince
Director/Board Member 41 2021-03-17
Director/Board Member 66 2021-03-21
Director/Board Member 58 2021-04-11
Date Insider Type Main position Quantity % Market Cap.
8/21/26 Buy

Chairman

10,000 0.0459%
8/3/26
Opaleye Management, Inc.
BuyCompany 50,000 0.2296%
7/24/26
Opaleye Management, Inc.
BuyCompany 130 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
-1.85%+11.66%+23.95%+49.90% 212M
+0.06%+2.35%+80.42%+126.59% 1,111B
+0.37%+0.73%+53.06%+64.26% 658B
+0.59%+2.70%+28.12%+81.28% 467B
+0.92%+3.57%+43.82%+44.21% 369B
+1.25%+2.21%+26.77%+43.05% 301B
+3.02%+5.68%+5.09%+17.04% 256B
+0.11%+4.41%+53.93%+73.19% 240B
+2.86%+3.86%-16.20%-51.83% 207B
+0.66%+2.84%+29.22%+91.92% 182B
Average +0.82%+5.07%+32.82%+53.96% 379.12B
Weighted average by Cap. +0.79%+4.68%+46.92%+73.37%

Financials

2026 *2027 *
Net sales 35.71M 25.8M 22.11M 20.72M 18.92M 2.46B 36.06M 244M 95.13M 1.24B 96.87M 94.76M 4.11B 68.4M 49.42M 42.35M 39.68M 36.25M 4.71B 69.08M 468M 182M 2.38B 186M 182M 7.87B
Net income -40.14M -29M -24.85M -23.29M -21.27M -2.76B -40.54M -275M -107M -1.39B -109M -107M -4.62B -19.9M -14.38M -12.32M -11.55M -10.55M -1.37B -20.1M -136M -53.02M -692M -53.99M -52.82M -2.29B
Net Debt - -
Logo Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Employees
-
Date Price Change Volume
26-08-25 US$9.550 -2.05% 61,196
26-08-24 US$9.750 0.00% 168,464
26-08-21 US$9.750 +2.63% 294,448
26-08-20 US$9.500 +6.86% 360,394
26-08-19 US$8.890 +3.67% 140,236
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.750USD
Average target price
18.00USD
Spread / Average Target
+84.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACOG Stock